Why Has Guardant Health (GH) Stock Increased This Session?


Guardant Health Inc (Nasdaq: GH) recently received coverage for its liquid biopsy test from a major national insurer, which has caused a surge in the stock price. On Wednesday, shares of Guardant Health rose 7.32% to reach a price of $30.65.

Who will be covering GH’s test?

Today, Guardant Health (GH) announced a major development in cancer treatment. A major healthcare insurer in the United States, UnitedHealthcare, has decided to cover all FDA-approved companion diagnostic indications for the Guardant360 CDx liquid biopsy test. Oncologists use this test to determine whether patients with advanced or metastatic breast or non-small cell lung cancer are eligible for targeted treatments. This diagnostic tool will now be available to patients covered by UnitedHealthcare’s commercial policies.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


A comprehensive genomic profiling of all solid tumors is available with the Guardant360 CDx blood test, the first approved by the US Food and Drug Administration. In order to guide the selection of personalized treatment options, this test provides a detailed analysis of the origin and genetic makeup of a patient’s cancer.

In addition to the Guardant360 CDx test being approved by the FDA, there is one to be used in treating advanced breast cancer and four for non-small cell lung cancer (NSCLC). To ensure that these treatments are effective and appropriate for each patient, the test is used in conjunction with them.

GH entered into a collaboration with

Guardant Health (GH) and AnHeart Therapeutics have recently partnered to revolutionize the diagnostic landscape for cancer patients through a strategic collaboration. As part of the partnership, Guardant360 CDx and Guardant360 TissueNext assays will be developed, approved and commercialized in both the United States and the European Union as companion diagnostics to taletrectinib. A precise and personalized approach to treatment will be provided by using genome profiling tests from GH, allowing the collaboration to identify patients with specific tumor mutations targeted by taletrectinib. In an effort to expedite the regulatory approval process and provide cancer patients with a new level of hope, this cutting-edge partnership aims to bring innovative diagnostic tools to market.


Please enter your comment!
Please enter your name here